If proven safe and effective to merit regulatory approval, these vaccines are poised to transform pandemic preparedness strategies moving forward. The development of messenger RNA (mRNA) and self-amplifying messenger RNA (samRNA) vaccines for COVID-19 has enabled the creation of effective interventions for seasonal influenza, pandemic influenza, and other public health emergencies. The goal of “better” vaccines can involve producing formulations that facilitate administration, improve vaccine efficacy, and/or expand indications across all population ages. The goal of “faster” influenza vaccines can involve application of more rapid RNA-based platforms to reduce the time required to deliver the final vaccine product, expansion of domestic vaccine manufacturing capacity to sustain production throughput, or acceleration and modernization of potency assay technology to improve vaccine release testing. Current manufacturing processes for influenza vaccines (e.g., egg-, cell-, and recombinant-based) are rate-limited by development steps such as candidate vaccine virus generation, process optimization, and release test times, thus extending timelines to first dose. The COVID-19 pandemic taught the world that next-generation pandemic vaccines must be better and more rapidly produced to enhance, diversify, and sustain our portfolio against public health emergencies caused by pandemic influenza and emerging infectious diseases. INVESTMENT AREASĭevelopment of Next-Generation Pandemic Influenza Vaccines As such, our Program’s mission aligns with BARDA’s new five-year Strategic Plan to strengthen efforts to protect Americans from any public health threat. Long-standing and ongoing partnerships are expanding these capabilities and addressing new threats. Since 2006, BARDA’s investments have transformed pandemic influenza vaccine preparedness, driving the nation’s responses to the Zika outbreaks (2016) and leading the medical countermeasure (MCM) response to the COVID-19 pandemic (2020–2022). This program promotes rapid vaccine development, timely regulatory clearance, and robust domestic manufacturing capacity to achieve the American Pandemic Preparedness Plan and HHS Pandemic Influenza Plan’s goals. The mission of the Influenza & Emerging Infectious Diseases (EID) Vaccines Development Program is to advance development and FDA approval of the best vaccine technologies to mitigate future outbreaks of pandemic influenza and other emerging infectious diseases. populations from pandemics and other public health emergencies due to influenza and emerging infectious diseases INFLUENZA VACCINES DEVELOPMENT PROGRAM OVERVIEW Frequently asked questions about COVID-19 vaccination.Ĭenters for Disease Control and Prevention.Influenza & Emerging Infectious Diseases Vaccines Development Programĭeveloping next generation vaccines that are more effective and can be deployed more quickly, and building robust domestic manufacturing capabilities to protect U.S. Quadrivalent influenza vaccine.Ĭenters for Disease Control and Prevention. Who Should and Who Should NOT Get a Flu Vaccine.Ĭenters for Disease Control and Prevention. US flu VE data for 2019-2020.Ĭenters for Disease Control and Prevention. Key facts about seasonal flu vaccine.Ĭenters for Disease Control and Prevention. Selecting viruses for the seasonal influenza vaccine.Ĭenters for Disease Control and Prevention. Influenza.Ĭenters for Disease Control and Prevention. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. Influenza vaccine effectiveness in preventing influenza-associated intensive care admissions and attenuating severe disease among adults in New Zealand 2012–2015. Thompson MG, Pierse N, Sue Huang Q, et al. Does influenza vaccination attenuate the severity of breakthrough infections? A narrative review and recommendations for further research. Preliminary Flu Vaccine Effectiveness (VE) Data for 2022-2023.įerdinands JM, Thompson MG, Blanton L, Spencer S, Grant L, Fry AM. doi: 10.15585/mmwr.rr7202a1Ĭenters for Disease Control and Prevention. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023–24 Influenza Season. Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 influenza season. Grohskopf LA, Blanton LH, Ferdinands JM, et al. Past seasons’ vaccine effectiveness estimates. CDC seasonal flu vaccine effectiveness studies.Ĭenters for Disease Control and Prevention. Centers for Disease Control and Prevention.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |